ELF3 and cardiomyopathy: On the other hand, we did not observe any significant increase in cardiomyocyte diameter or vacuolated surface area during the two years of treatment; while our study did not include any untreated controls, these findings suggest that ERT may stabilize the cardiomyopathy at least in its early phase.